Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Submitted by
admin
on October 29, 2023 - 8:44pm
Source:
Motley Fool
News Tags:
Roche
Eli Lilly
Pfizer
IBD
ulcerative colitis
Crohn's Disease
mirikizumab
Headline:
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
snippet:
Roche spent $7.1 billion on a company, primarily because of an IBD therapy.
Pfizer just got approval for a pill to treat ulcerative colitis.
Eli Lilly just reported promising trial data for its IBD therapy, mirikizumab.
Do Not Allow Advertisers to Use My Personal information